Individuals with chronic obstructive pulmonary disease (COPD) have long been identified to have an elevated serum level of angiotensin‐converting enzyme 2 (ACE2), the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The newest discoveries by Higham et al. (1) were the increased ACE2 expression in the bronchial epithelium of overweight COPD patients compared to their non‐overweight counterparts.
FingerprintDive into the research topics of 'The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19'. Together they form a unique fingerprint.
Press / Media
7/07/20 → 13/07/20
13 items of Media coverage